Kringle Pharma, Inc.

Equities

4884

JP3270790003

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-17 EDT			5-day change	1st Jan Change
650 ^JPY	+13.24%		+19.27%	-13.56%

02-09	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI
2023	Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	CI

Kringle Pharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022

November 13, 2022

Kringle Pharma, Inc. reported earnings results for the full year ended September 30, 2022. For the full year, the company reported sales was JPY 391.83 million compared to JPY 289.76 million a year ago. Net loss was JPY 331.83 million compared to JPY 301.17 million a year ago.

Basic loss per share from continuing operations was JPY 68.33 compared to JPY 72.51 a year ago.

Latest news about Kringle Pharma, Inc.

Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	02-08	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	11-28	CI
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	11-17	CI
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries	23-10-31	MT
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	23-10-30	CI
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	23-10-02	CI
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	23-09-03	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-08-30	CI
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	23-08-13	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-05-29	CI
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment	23-04-14	MT
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	23-04-13	CI
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment	23-03-14	MT
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	23-03-12	CI
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	23-02-27	CI
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine	23-01-18	MT
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment	23-01-18	MT
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	23-01-16	CI
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	23-01-12	CI
Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023	22-12-01	CI
Japan Shares Turn Red on Tokyo Inflation, Protests Over China Lockdown; Shionogi Seeks COVID-19 Vaccine Approval	22-11-25	MT
Kringle Pharma Starts Clinical Trial for Treatment of Vocal Impairment; Shares Up 7%	22-11-25	MT
Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold Scar	22-11-23	CI
Kringle Pharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-13	CI
Kringle Pharma Seeks Clinical Trial Approval for Treatment of Vocal Impairment	22-10-25	MT

Chart Kringle Pharma, Inc.

Duration

Period

More charts

Company Profile

Kringle Pharma Inc is a Japan-based company mainly engaged in the development of pharmaceuticals. The Company is involved in the research and development of therapeutic agents for intractable diseases using hepatocyte growth factor (HGF) protein. HGF has versatile bioactivity that is responsible for tissue or organ regeneration and protection such as cell proliferation promotion, cell motility promotion, anti-apoptosis, morphogenesis induction, and angiogenesis. HGF has a therapeutic effect on chronic fibrotic diseases such as liver cirrhosis, chronic renal failure, pulmonary fibrosis and cardiomyopathy. HGFs target diseases are Atrophic lateral sclerosis (ALS), Acute renal impairment, Vocal scar and others. The Company is involved in the general new drug development processes such as basic research, non-clinical trials and manufacturing, clinical trials, approval application and authorization, marketing and expansion of indications.

Sector

Biotechnology & Medical Research

Calendar

2024-11-10 - Q4 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
KRINGLE PHARMA, INC.	-13.56%	27.48M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B

Other Biotechnology & Medical Research